Phosphatase of regenerating liver (PRL)-3 is highly expressed in multiple cancers and has important roles in cancer development. Some small-molecule inhibitors and antibodies targeting PRL-3 have been recently reported to inhibit tumor growth effectively. To determine whether PRL-3-targeted DNA vaccination can induce immune response to prevent or inhibit the tumor growth, we established mouse D2F2 breast cancer cells expressing PRL-3 (D2F2/PRL-3) and control cells (D2F2/NC) with lentivirus, and constructed pVAX1-Igk-PRL-3 plasmid (named as K-P3) as DNA vaccine to immunize BALB/c mice. We found that the K-P3 vaccine delivered by gene gun significantly prevented the growth of D2F2/PRL-3 compared with pVAX1-vector (Po0.01), but not of D2F2/ NC, and improved the survival of D2F2/PRL-3-innoculated mice. Both PRL-3-targeted cytotoxic T lymphocytes (CTLs) and T-helper type 1 cell immune response (production of high levels of interferon-g and tumor necrosis factor-a) were found to be involved in the preventive effect. Furthermore, PRL-3-targeted DNA immunization inhibited tumor growth of D2F2/PRL-3 cells in mice. We also evaluated the potential of immunization with PRL-3 protein, but no significant therapeutic or preventive effect was obtained on tumor growth. To enhance the immunity of PRL-3, we incorporated different molecular adjuvants, such as Mycobacterium tuberculosis heat-shock protein, CTL antigen 4 and M. tuberculosis T-cell stimulatory epitope (MT), into K-P3 vaccine for expressing the fusion proteins. We found that these adjuvant molecules did not significantly improve the antitumor activity of PRL-3 vaccine, but enhanced the production of PRL-3 antibodies in immunized mice. Summarily, our findings demonstrate that PRL-3-targeted DNA vaccine can generate significantly preventive and therapeutic effects on the growth of breast cancer expressing PRL-3 through the induction of cellular immune responses to PRL-3.
INTRODUCTION
Protein tyrosine phosphorylation has a major role in cellular signaling. The level of tyrosine phosphorylation is controlled by protein tyrosine kinases and protein tyrosine phosphatases (PTPs). 1 Aberrant tyrosine phosphorylation by dysregulated PTP activity has been implicated in the progression of various diseases, including cancer. 2 Phosphatase of regenerating liver (PRL)-3, also known as PTP4A3, is a member of PTP superfamily and characterized by its tyrosine phosphatase domain and a C-terminal prenylation (CCVM) motif. 3 PRL-3 was reported to be highly expressed in several cancers and promote cancer cell invasion and metastasis. 4, 5 Our previous works showed that PRL-3 was aberrantly expressed in breast cancer, colorectal cancer and ovarian cancer, which was associated with poor clinical outcome.
6-9 PRL-3 was also shown to promote epithelialmesenchymal transition by downregulating cadherin-like protein 22 and E-cadherin. [10] [11] [12] Increasing evidences suggest that PRL-3 has an important role in tumorigenesis and cancer metastasis, and is a potential target for cancer therapy. 4 Small-molecule inhibitors and antibodies targeting PRL have been reported recently. 13 The PRL-3 inhibitors, such as pentamidine, 14 rhodanine, 15 thienopyridone (7-amino-2-phenyl-5H-thieno [3, 2-c] pyridine-4-one), 16 curcumin, 17 and prenylation transferase inhibitor FTI-277, 3 were shown to be effective in inhibiting tumor growth. The antibodies against PRL-1 and PRL-3 could dramatically reduce the growth of PRL-1-and PRL-3-expressing metastatic lung tumors in nude mice. Monoclonal antibody to PRL-3 reduced the growth of PRL-3-proficient A2780 cells, but not PRL-3-deficient CT26 cells in vitro and in vivo. 18 In C57BL/6 mice, injection of antibody to PRL-3 effectively retarded metastatic cancers expressing PRL-3, and PRL-3 protein-induced host antibodies upon vaccination could specifically inhibit the formation of tumors. 19 Furthermore, PRL-3 human/mouse chimeric antibody is likely to have broad applications in reducing the formation of PRL-3-expressing metastatic tumors. 20 DNA vaccine using naked plasmid DNA expressing the associated antigen to activate the immune system has emerged as a favorable approach for antigen-specific immunotherapy for the safety, flexible, stability, ease of production and storage, and induction of antigen-specific T-and B-cell responses. 21, 22 Several preclinical studies on mice immunized with various DNA vaccines have reported high antigen-specific immunity against established tumors or pathogens. [23] [24] [25] [26] [27] [28] However, the utilization of DNA immunization targeting PRL-3 has not been explored.
In this study, we sought to determine whether PRL-3 DNA vaccination could induce immune response against PRL-3-expressing tumors in a mouse breast cancer model. PRL-3 protein contains different epitopes that might be presented by dendritic cells and thus used as targets for cancer vaccination. 29 As human PRL-3 shares 96% identity in amino-acid sequences with mouse PRL-3, 30 we used the human PRL-3 gene as an antigen to overcome immune tolerance to PRL-3 in mice and tested different PRL-3 DNA vaccine strategies for the induction of tumor rejection and therapy. We also compared the therapeutic and preventive efficiencies of DNA vaccine with those of protein vaccine. Although there are various DNA vaccine delivery methods being investigated, such as intramuscular, electroporation and bacterial magnetic nanoparticles, 31 we used the gene gun delivery system because it could bombard DNA directly into intracellular spaces of targeted tissues (for example, the professional antigen-presenting cells in the skin) to elicit high transfection efficiency and immunogenicity. 32 We found that PRL-3 DNA vaccination by gene gun delivery system suppressed the growth of breast cancer mainly by inducing cellular immune response against PRL-3.
RESULTS

Establishment of D2F2 cell lines stably expressing PRL-3
To investigate the preventive and therapeutic effects of PRL-3-targeted DNA immunization on tumors, the mouse mammary tumor cell line D2F2 derived from a spontaneous mouse mammary tumor 25 was infected with the lentiviral-PRL-3 or the control lentiviral vector, and green fluorescent protein (GFP) was used as infection reporter, which was not fused to PRL-3 ( Figure 1a ). The exogenous PRL-3 expression was further quantitatively examined by real-time reverse transcription-polymerase chain reaction (RT-PCR) and western blot analysis in D2F2/ PRL-3 and D2F2/NC cells, and no endogenous PRL-3 was detected (Figure 1b) . To evaluate the functional consequence of PRL-3 overexpression, we performed cell proliferation assay and found that the overexpression of PRL-3 did not affect the cell proliferation (P ¼ 0.9116; Figure 1c) . However, the migration of D2F2/PRL-3 was significantly increased compared with that of D2F2/NC cells (Supplementary Figure S1a ; Po0.001), which is consistent with the promigrating function of PRL-3. 3, 10, 33, 34 Preventive effect on tumor growth by K-P3 DNA vaccination To investigate whether the PRL-3 DNA vaccination could prevent tumor growth, we constructed pVAX1-Igk-PRL-3 plasmid (named as K-P3; Figure 2a ) and confirmed its secreted expression in QM7 (Quail muscle clone 7) cells by western blot analysis (Figure 2b ). QM7 cells were derived from the quail fibrosarcoma cell line QT6, 35 which was proved to be a novel eukaryotic expression system in combination with cytomegalovirus promoter-based expression vector. 36 Igk, as a usual leader (signal) sequence, was constructed into the pVAX1 expression vector containing cytomegalovirus promoter to enhance the secretion of the heterologous PRL-3 protein expressed in QM7 cells (Figure 2b) .
We then immunized BALB/c mice with the K-P3 plasmid by gene gun delivery, followed by injection of D2F2/NC or D2F2/PRL-3 tumor cells (Figure 2c ). The plasmid DNA-coated gold particles were propelled into the skin by a short pulse of pressurized helium gas, and were observed in the dermis (Figure 2d ). We found that the D2F2/PRL-3 tumors grew much more progressively in pVAX1-immunized mice (red line) than in K-P3-immunized mice (blue line) (Po0.01), but the D2F2/NC tumors grew similarly in either K-P3 DNA-or pVAX1-vaccinated mice (Figure 2e ). The KaplanMeier method was used to analyze the survival of these mice. We found that the K-P3 DNA vaccination significantly prolonged the survival time of the D2F2/PRL-3 mice with a median survival of 53 days compared with D2F2/PRL-3 mice immunized with pVAX1 (38 days, P ¼ 0.0048, by log-rank test), whereas D2F2/NC mice had similar median survivals in either the K-P3 (34 days) or pVAX1 immunization (35.5 days) (Figure 2f To determine the mechanism underlying PRL-3 DNA immunization-modulated T effector cell differentiation, the levels of interferon (IFN)-g, tumor necrosis factor (TNF)-a, interleukin (IL)-4 and IL-10 in the splenocytes culture supernatants were measured by enzymelinked immunosorbent assay (ELISA) assays. As shown in Figures 2h and i, the levels of IFN-g and TNF-a in supernatants at 48 h were at least twofold higher in the group of mice inoculated with D2F2/PRL-3 cells and immunized with K-P3 DNA than those of mice inoculated with D2F2/NC or immunized with pVAX1. However, only low levels of IL-4 and IL-10 were detected in those supernatants (Figures 4e  and f) . These results suggested that T-helper type 1 cell immune response played a dominant role in tumor rejection and the K-P3 vaccine overcame possible involvement of regulatory T cells.
Adjuvant-PRL-3 DNA vaccination for tumor prevention To explore the possibility of enhancing the preventive immunity of PRL-3 vaccine against tumor, we utilized Mycobacterium tuberculosis heat-shock protein (TBhsp), 37 CTL antigen 4 (CTLA4) 38 and M. tuberculosis T-cell stimulatory epitope (MT) 39, 40 as 'molecular adjuvants' for their well-characterized enhancement of immune potency. By using pVAX1 vector as backbone, we constructed different DNA vaccines encoding adjuvant-PRL-3 fusion proteins, including K-P3-MT, K-T-P3, K-T-P3-MT, K-C-P3 and K-C-P3-MT (Figure 3a) , whose expression were detectable in both QM7 cell lysates and the culture supernatant ( Figure 3b ). Then, we evaluated their suppressive effects on tumor growth through gene gun-mediated delivery. Growth of D2F2/PRL-3 tumors was inhibited in the mice immunized with adjuvant-PRL-3 DNA, but no enhancement in the antitumor activity was observed in the adjuvant-PRL-3 DNA vaccines compared with the K-P3 DNA vaccine alone (blue line) ( Figure 3c ). Also no significant improvement in survival of the mice was achieved (Figure 3d ). In addition, D2F2/NC tumors displayed similar growth kinetics in all the immunized groups (Supplementary Figure S1c) , and the adjuvant-PRL-3 DNA vaccines 
Adjuvant-PRL-3 DNA vaccination for induction of humoral and T-cell immunities
To analyze the humoral immune response against PRL-3 in BALB/c mice, the sera were collected from the immunized mice and anti-PRL-3 antibody was determined with ELISA assay. The levels of PRL-3 antibodies in mice immunized with K-P3-MT, K-T-P3, K-C-P3 and K-C-P3-MT were higher than those immunized with K-P3 or pVAX1 vector, and no difference in PRL-3 antibody levels was found between K-P3 and pVAX1 vector (Figure 3e ).
To assess the cellular immune response induced by the different adjuvant-PRL-3 vaccines, isolated splenocytes were restimulated with His-P3, His-P3-MT, His-T-P3 or His-C-P3 fusion protein Preventive effect on tumor growth by PRL-3 protein vaccination To compare preventive efficacy of the PRL-3 DNA vaccination with that of protein immunization, BALB/c mice were immunized with the PRL-3 protein by intraperitoneal injection with Freund's adjuvant basically as described by Guo et al., 19 followed by injection of D2F2/ PRL-3 tumor cells (Figure 5a ). We found that the D2F2/PRL-3 tumors grew slowly in PRL-3 protein-immunized mice (black line) than in control protein (NC)-immunized mice (gray line) on the 15th and 21st day (Po0.01). However, by the 29th day no difference in the D2F2/PRL-3 tumors volumes was observed between two groups (Figure 5b ). There was no statistically significant difference in survival time between the two groups ( Figure 5c ).
Mice immunized with PRL-3 protein produced higher titers of PRL-3 antibodies than those immunized with NC protein (Figure 5d ) or DNA vaccines (Figure 3e ). Elevated levels of IFN-g (gray column) and IL-4 (black column) in PRL-3 protein immunization were revealed by quantitative RT-PCR (Figure 5e ). CTLs generated from mice immunized with PRL-3 protein (black line) exhibited higher CTL activities compared with those from the mice immunized with NC protein (gray line) when D2F2/PRL-3 cells were used as target cells (Figure 5f ).
Therapeutic effect on tumor growth by K-P3 DNA or PRL-3 protein immunization To investigate whether PRL-3 DNA immunization could induce therapeutic immunity against tumor, BALB/c mice were inoculated Vaccination against PRL-3 inhibits tumor growth J Lv et al with D2F2/NC or D2F2/PRL-3 tumor cells. When the tumors were palpable, the mice were immunized with K-P3 DNA or pVAX1 vector by gene gun delivery (Figure 6a ). The K-P3 DNA immunization significantly suppressed the growth of D2F2/PRL-3 (blue line), while the D2F2/NC and D2F2/PRL-3 tumors in the mice treated with pVAX1 vector and the D2F2/NC tumors in the mice immunized with K-P3 DNA displayed similar growth kinetics (Figure 6b ). K-P3 DNA immunotherapy prolonged the survival time of the D2F2/PRL-3 tumor-bearing mice with a median survival of 50 days, but did not obtain a statistically significant difference from that of the pVAX1 control (Figure 6c ;
Comparison of the PRL-3 DNA vaccination with the PRL-3 protein immunization was further performed. BALB/c mice were immunized with the PRL-3 protein or the NC protein by intraperitoneal injection with Freund's adjuvant after being inoculated with D2F2/PRL-3 tumor cells (Figure 6d) . Compared with the NC protein immunization (gray line), PRL-3 protein immunization marginally restrained the growth of D2F2/PRL-3 tumors (Figure 6e , black line), and it did not improve the survival of the mice (Figure 6f ).
DISCUSSION
In this study, we investigated the preventive and therapeutic effects of DNA vaccines encoding secretable PRL-3 fusion proteins with leader sequences Igk and various adjuvant molecules (TBhsp, CTLA4 and MT). Despite some differences in the capacity of inducing immune responses, we observed that PRL-3 DNA vaccines have marked preventive effects on D2F2 tumor cells overexpressing PRL-3 and have therapeutic activities in inducing tumor regression (summarized in Table 1 ).
The weak antigenic nature of cancer demands for novel vaccination strategies that elicit fully immune responses in immune damaged or tolerant conditions. 41 We designed the PRL-3-targeted DNA vaccines by incorporating the Kozak sequence and Igk leader (signal) sequence into the pVAX1 plasmid backbone for all the PRL-3 DNA vaccine constructs. The Kozak sequence is used to improve the expression of the transgene product in mammalian cells. 42 The addition of Igk leader sequences could improve the mRNA stability and protein translation efficiency, 22 and guide the expressed protein to the endoplasmic reticulum to promote induction of humoral and CD8 þ T-cell responses. 43 In our study, the Igk also enhanced the In addition, we utilized gene gun immunization to deliver DNA, which allowed direct presentation of the antigen to dendritic cells, and indirect cross-presentation of exogenous antigen from nonimmune cells in the skin. 44 Likewise, the secreted PRL-3 antigen may be taken up and presented by professional antigenpresenting cells through cross-priming pathways. 32 Tumor antigens can be presented by DNA in a suitable molecular form from the full-length protein, to induce an antibody response, to short major histocompatibility complex class I or II peptides, to optimize the induction of T-cell responses. 45 Compared with the pVAX1 control, PRL-3 DNA vaccines generated greater levels of the PRL-3-specific cytotoxic T lymphocytes. The specificity of killing was demonstrated by the inability of the splenocytes from PRL-3-vaccinated mice to kill D2F2/NC cells expressing no PRL-3 antigen. Thus, both the pVAX1 control and PRL-3 DNA vaccines could not retard the tumor growth in the D2F2/NC tumor-bearing mice, and the pVAX1 control had no significant effect on the growth of the D2F2/PRL-3 cells overexpressing PRL-3 antigen. The effect of PRL-3 on cell proliferation was found to be cell type-specific; 46 however, its proinvasive potential is well documented. 3, 10, 33, 34 In this study, the overexpression of PRL-3 did not affect the proliferation of D2F2 cells, but we did find that ectopic PRL-3 promoted cell migration, consistent with its oncogenic roles in tumor development. Our results further validates PRL-3 as a potential target for DNA vaccine because of its frequent overexpression in diverse types of tumor.
Several ways are currently available to improve antigen expression and immunogenicity for DNA vaccination. For instance, immune adjuvants have been evaluated by using immune modulatory molecules targeting death receptors ligands, growth factors, adhesion molecules, cytokines and chemokines, and toll-like receptors. 22 The strong antigenic nature of TBhsp is evidenced by the fact that mammals can recognize multiple B-and T-cell epitopes in this protein, which are located in half of its ATP-binding domain (amino acids 161-370), making hsp's attractive in immunotherapy. 37 This strategy activates high levels of T-helper cell, the key for the induction and maintenance of effective immunity. 41 MT, T-cell stimulatory epitope (DQVHFQPLPPAVVKLSDAL), is from the 38 kDa lipoprotein of the M. tuberculosis. Previous studies demonstrated that tagging the antigen with the MT could further boost the immune response, which was stronger than that induced by the GST-HMGB1 fusion protein. 40 The targeted transfer of antigens from vaccine-expressing cells to antigen-presenting cells could enhance both cross-presentation and the efficiency of DNA vaccination. CTLA4 is an essential negative regulator of T-cell-mediated immune responses and multiple studies have demonstrated that CTLA4 mediates binding to B7-expressing cells to allow the attached antigens specifically targeted to antigen-presenting cells for uptake and presentation. 38 Herein, we attempted to use the above adjuvant molecules to explore the possibility of enhancing the preventive immunity of PRL-3 vaccine against tumor. Our results indicated that the addition of adjuvant molecules of TBhsp, CTLA4 and MT did not generate significant enhancement in inhibiting tumor progression or improving the survival of the mice compared with the K-P3 vaccine alone. This may be due to the fact that these adjuvant-PRL-3 DNA vaccines were constructed in a single open reading frame, which could have unpredictable physical and immunological properties. Furthermore, simultaneous in situ expression of the strong immunogenic adjuvant and weak immunogenic tumor antigens could promote immune response to the helper antigen rather than to the target antigen. 47 Therefore, the codelivery of the two plasmids, respectively, encoding the adjuvant and target antigens at an optimized ratio in the same gold particles via gene gun could be an alternative approach. 47 In addition, the immunosuppressive environment created by tumors spreading to draining lymph nodes can enhance regulatory T cells, which suppress the T effector cell function. 45 Other suppressive lymphocyte subsets have been reported, including IL-10-producing B cells and B regulatory cells, type II NKT cells, NK cells and gdT cells. 29 IL-10 induces regulatory T cells and dampens the immunity to self-antigens. 48 In our study, we observed that the level of IL-10 was as high as IFN-g and TNF-a in the mice vaccinated with the adjuvant-PRL-3 vaccines, which may suppress the immune response to the PRL-3 following vaccination.
On the other hand, our data showed that the mice immunized with adjuvant-PRL-3 DNA vaccines elicited higher levels of PRL-3 antibodies in their serum than in the K-P3 vaccine or pVAX1 control groups. This result suggested that it may be useful to incorporate the molecule adjuvant into the antigen to improve antibody generation. Although vaccination with the fusion vaccines could elicit specific CTL responses in vitro and efficient antitumor immunity in a D2F2/PRL-3 mouse model, the molecule 
Abbreviations: CTL, cytotoxic T lymphocytes; ELISA, enzyme-linked immunosorbent assay; IFN, interferon; IL, interleukin; MST, median survival time; ND, no data; PRL, phosphatase of regenerating liver; TNF, tumor necrosis factor. IFN-g, TNF-a, IL-4 and IL-10: Cytokines' secretion determined by ELISA. '' À '' , had no effects or activities; '' þ '' , had effects or activities; ''±'' , had weak effects or activities.
Vaccination against PRL-3 inhibits tumor growth J Lv et al adjuvants had no significant improvement in the median survival compared with K-P3. A previous study demonstrated that antibodies to PRL-3, EGFP and MT or antigen-induced antibodies therapies against intracellular targets could inhibit tumor progression in C57BL/6 EGFP-B16F0 melanoma tumor-bearing mice or MMTV-PymT transgenic breast tumor mice, respectively. 19 Some explanations could be envisioned for that result: one could be that a small fraction of intracellular antigens was released partly because of necrosis or cancer cell lysis, and the other was that the antibodies could be taken up by the cancer cells in an antigen-specific manner, or the proteolytic fragment of intracellular antigens might be presented by major histocompatibility complex I to attract CTLs. 19, 49 We found that PRL-3 DNA vaccination had a significant potential in the therapeutic and protective efficacy compared with protein immunization (summary information in Table 2 ). The distinct efficacies of DNA and protein immunization could be explained by the difference in immunogenicity. In DNA vaccination, the plasmids can be delivered directly into intracellular spaces of targeted skin tissues, and then use the host cellular machinery to reproduce protein with native conformations having more epitopes, which can be the subject of immune system in the context of both major histocompatibility complexes I and II in the immunized individual. 22 However, the protein antigens injected into host tends to be deficient in native conformations, thus limiting the epitopes recognized by the immune system ECL system (Pierce, Rockford, IL, USA).
Although we used a similar protein immunization approach as the one described by Guo et al. 19 and one that could produce specific PRL-3 antibodies and CTLs, these immune responses did not achieve significant therapeutic or protective effects in the D2F2 breast cancer system. The discrepancy in the results of PRL-3 protein immunization may be due to the different cancer cell lines used. Moreover, there was an unbalance between humoral and cellular immunity because of robust generation of anti-PRL-3 antibodies upon PRL-3 protein immunization (Figures 5d-f) . High level of PRL-3 antibodies might react with the antigen to form antigen-antibody complexes in the circulation, which could damage tissues by triggering inflammation, 50 rendering PRL-3 protein-immunized mice die faster than those immunized with control protein (Figures 5c and 6f) .
Our study supports that the strategy of the PRL-3 DNA vaccine via gene gun immunization is workable to suppress breast tumor growth, and the suppressive effect of the PRL-3 DNA vaccine on tumor growth is tightly correlated with the PRL-3 expression status in cancer cells. In future studies, we will further investigate the roles of immune effector cell subsets in tumor prevention and develop more optimized immunization strategies for the PRL-3 vaccine to eventually apply to patients with or at risk of cancer.
MATERIALS AND METHODS
Cell culture
Mouse mammary tumor cell line D2F2 was maintained in our laboratory and cultured in RPMI 1640 medium, supplemented with 10% fetal bovine serum (Invitrogen, San Diego, CA, USA), penicillin G (100 U ml À 1 ), streptomycin (100 mg ml À 1 ). QM7 cells were kindly provided by Dr Z ZhiQian (Peking University Cancer Institute) and cultured in Medium 199 with Earle's balanced salt solution, supplemented with 10% fetal bovine serum, 10% tryptose phosphate broth, 2 mM L-glutamine and 0.5% chicken embryo extract. 36 All cells were incubated at 37 1C in a humidified atmosphere of air with 5% CO 2 .
Plasmids for DNA vaccination
The mammalian expression vector pVAX1 (Invitrogen) was used as a backbone for the construction of DNA vaccines. The generations of pGEX-4T1-PRL-3 and pVAX1-Igk have been described previously. 51, 52 In brief, the oligonucleotide primers consisting of the Kozak sequence, the Igk leader peptide and myc tag (5 0 -AGCTTTCGCCACCATGGAGACAGACACACTC CTGCT ATGGGTACTGCTGCTCTGGGTTCC AGGTTCCACTGGTGACGAGCAGAAGCTG ATCAGCGAGGAGGACCTGG-3 0 and 5 0 -GATCCCAGGTCCTCCTCGCTGATCAGC TTCTGCTCGTCACCAGTGGAACCTGGAACCCAGAGCAGCAGTACCCATAGCAG GAGTGTGTCTGTCTCCATGGTGGCGAA-3 0 ) were designed to incorporate HindIII and BamHI restriction enzyme sites flanking the adhesive ends (underlined) after renaturation to insert into HindIII/BamHI-digested pVAX1.
Plasmid pVAX1-Igk-PRL-3 encoding the full length of human PRL-3 with stop codon was derived by subcloning PRL-3 as BamHI/EcoRI fragment from pGEX-4T1-PRL-3 into BamHI/EcoRI-digested pVAX1-Igk. To generate pVAX1-Igk-PRL-3-MT, the PRL-3 DNA fragment without stop codon was amplified using PCR with primers designed to incorporate BamHI and EcoRV/NotI (underlined) (5 0 -CGCGGATCCATGGCTCGGATGAACC-3 0 and 5 0 -TTTGCGGCCGCGATATCCATAACGCAGCACC-3 0 ) and pGEX-4T1-PRL-3 as a template. The PCR product digested with BamHI and NotI was further inserted into BamHI/NotI sites of pVAX1-Igk to form pVAX1-Igk-PRL-3 (PCR). Then, the 19 residue sequences of the mycobacterial 38-kDa protein (350-368) (MT) 40 oligonucleotide primers (5 0 -ATCGACCAGGTTCATTTCCA GCCGCTGCCGCCCGCGGTGGTGAAGTTGTCT; GACGCGTTGTAAGC-3 0 and 5 0 -GGCCGCTTACAACGCGTCAGACAACTTCACCACCGCGGGCGGCAGCGGCTGGA AATGAACCTGGTCGAT-3 0 ) were designed to incorporate EcoRV and NotI restriction enzyme sites flanking the adhesive ends (underlined) after renaturation to facilitate in-frame cloning into the pVAX1-Igk-PRL-3 (PCR) C terminus.
The DNA fragment encoding the amino acids 161-370 of TBhsp 37 was a gift from Q-Z Zhao (Cancer Institute and Hospital, Peking Union Medical College and Chinese Academy of Medical Science, Beijing, China). To generate pVAX1-Igk-TBhsp (abbreviated to K-T), a forward primer containing a BamHI site (underlined) (5 0 -GATCGGATCCGAGAAGGAGCA GCGAATCCTG-3 0 ) immediately before the TBhsp peptide-encoding sequence and a reverse primer containing BglII/EcoRI sites (5 0 -GTCA GAATTCAGATCTCGGGGTAACATCAAGCAG-3 0 ) without stop codon were used for PCR amplification. The PCR product was digested with BamHI and EcoRI and inserted into BamHI/EcoRI-digested pVAX1-Igk. For construction of plasmid pVAX1-Igk-CTLA4 (K-C), a cDNA fragment encoding the extracellular domain of mouse CTLA4 was digested with BamHI/EcoRI from pUC57-CTLA4 and inserted into BamHI/EcoRI-digested pVAX1-Igk. 
Need protein purification
Abbreviations: CTL, cytotoxic T lymphocytes; IFN, interferon; IL, interleukin; MST, median survival time; ND, no data; PCR, polymerase chain reaction; TNF, tumor necrosis factor. '' À '' , had no effects or activities; '' þ '' , had effects or activities; '' ± '' , had weak effects or activities.
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The PRL-3 fragment from pVAX1-Igk-PRL-3 by BamHI and EcoRI digestion was subcloned into BglII/EcoRI-digested K-T and K-C plasmid, respectively, yielding pVAX1-Igk-TBhsp-PRL-3 (K-T-P3) and pVAX1-Igk-CTLA4-PRL-3 (K-C-P3). Likewise, the fragment PRL-3-MT was digested with BamHI and NotI from pVAX1-Igk-PRL-3-MT and inserted into BglII/NotIdigested K-T and K-C plasmid, to generate pVAX1-Igk-TBhsp-PRL-3-MT (K-T-P3-MT) and pVAX1-Igk-CTLA4-PRL-3-MT (K-C-P3-MT).
All plasmid constructs were confirmed by DNA sequencing. pVAX1 vector plasmid was used as a control. Large-scale purification of plasmid DNA was performed using the Vigorous Plasmid Maxprep Kit (Vigorous Biotechnology Beijing Co. Ltd, Beijing, China) according to the manufacturer's protocol. The purified plasmid DNA was resuspended in sterile Tris-EDTA buffer at a final concentration of 1 mg ml À 1 for DNA vaccination.
Transient transfection and western blot analysis QM7 cells were transiently transfected with plasmids encoding various adjuvant-PRL-3 fusion proteins by Lipofectamine2000 (Invitrogen) following the instructions of the manufacturer. Cells harvested 48 h post transfection were homogenized in lysis buffer and lysates were subjected to western blot as described previously. 10 Anti-PRL-3 monoclonal antibody (clone no. 3B6; Peng et al.
52
) was used as a primary antibody and the protein bands were visualized with the ECL system (Pierce, Rockford, IL, USA).
Construction and expression of adjuvant-PRL-3 fusion proteins
pET-28a-PRL-3 was maintained in our laboratory. pET-28a-PRL-3-MT was generated by ligating BamHI/NotI-digested PRL-3-MT from pVAX1-Igk-PRL-3-MT to BamHI/NotI-digested pET-28a vector (Novagen, Billerica, MA, USA). Likewise, the fragments of T-P3 and C-P3 digested with BamHI/XhoI from pVAX1-Igk-T-P3 and pVAX1-Igk-C-P3 were inserted into BamHI/XhoIdigested pET-28a vector to generate pET-28a-T-P3 and pET-28a-C-P3, respectively. These recombinant His-tagged PRL-3 or adjuvant-PRL-3 fusion protein were expressed in and purified from BL21 E. coli as previously described. 53 
Overexpression of PRL-3 by lentiviral infection
To generate D2F2 cells stably expressing PRL-3 (D2F2/PRL-3) and the control cells (D2F2/NC), the lentivirus vectors were constructed, packed and purified by GenePharma Co. Ltd (Shanghai, China). D2F2 cells (5 Â 10 4 per well) in a six-well plate were infected with the lentiviral-PRL-3 or control lentiviral vector at a multiplicity of infection ¼ 200 in the presence of 5 mg ml À 1 polybrene. At 24 h after the infection, the medium was replaced with 3 ml complete culture medium. After 60 h, PRL-3 expression was examined by quantitative real-time PCR and western blot analysis.
Quantitative real-time PCR Total RNA from D2F2/PRL-3 and D2F2/NC cells isolated using TRIZOL reagent (Invitrogen) were subjected to quantitative real-time PCR (qRT-PCR). 54 Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the internal control gene. Target gene expression was normalized to GAPDH and analyzed by the 2 À DDCT formula. Reactions were performed using SYBR Green (Applied Biosystem, Foster City, CA, USA) according to the manufacturer's instructions. Setting for amplification was 95 1C for 
Cell proliferation and migration assay
A total of 5 Â 10 4 D2F2/NC or D2F2/PRL-3 cells in 2 ml of culture medium were added in each well of 6-well plates in triplicate for proliferation assay on day 0. Cells were harvested and counted in 24-h interval as described previously. 55 Cell migration assay was performed as described previously 10 using 8.0-mm pore size Transwell inserts (Costar, Cambridge, MA, USA).
Animals and DNA vaccination
Animal studies were approved and supervised by the Biomedical Ethical Committee of Peking University Cancer Hospital and Institute. Inbred 6-to 8-week-old female immunocompetent BALB/c mice (Vital River Laboratories, Beijing, China) were maintained under specific pathogen-free conditions. The Helios Gene Gun system (Bio-Rad, Hercules, CA, USA) was used for intradermal gene delivery. Bullets containing plasmid DNA were generated basically as described by Qin et al.. 23 Each cartridge contained 1.2 mg of plasmid DNA mixture (1.2 mg per bullet) and each mouse received two shots by gene gun bombardment for a total of 2.4 mg per mouse.
Preventive and therapeutic DNA vaccination by gene gun Female BALB/c mice (n ¼ 5 or 10-12 per group) were immunized with various plasmid constructs two times at 2-week intervals using gene gun and the dose described above. Control mice were treated with the pVAX1 vector alone. At 2 weeks after the second immunization, the mice were implanted in the left mammary fat pad with 2 Â 10 5 D2F2/PRL-3 or D2F2/ NC cells in phosphate-buffered saline per mouse. Once tumor became palpable, they were measured every 5 days with calipers until the end of the experiment. Tumor volume was calculated using the following formula: V ¼ length Â (width) 2 /2. Differences in the survival rates were determined by log-rank test.
For therapeutic vaccination, female BALB/c mice (n ¼ 10-12 per group) were first inoculated with D2F2/PRL-3 or D2F2/NC cells as described above. On day 7 after tumor cell injection, when tumors were palpable, mice were immunized with K-P3 or the control pVAX1 vector two times at 2-week intervals using gene gun and the dose described above. Control mice were treated with the pVAX1 vector alone. Tumor growth was measured as described above.
Histological examination
After DNA vaccination, mice skin tissues from the bombardment sites were surgically excised, fixed for 24 h in 10% neutral-buffered formalin, embedded in paraffin, sectioned at 6 mm thickness and stained with hematoxylin and eosin for histological examination.
Preventive and therapeutic protein vaccination
Recombinant GST-PRL-3 and GST protein were expressed in and purified from BL21 E. coli transformed with pGEX4T1-PRL-3 and pGEX4T1. 52 Female BALB/c mice (n ¼ 10 per group) were firstly immunized by intraperitoneal injection, as described by Guo et al., 19 with 50 mg GST-PRL-3 protein in 100 ml phosphate-buffered saline mixed with 100 ml Freund's completed adjuvant (Sigma, St Louis, MO, USA). Control mice were immunized by intraperitoneal injection using the same amount of GST protein. The next immunization was injected similarly except with the incomplete adjuvant at 2-week intervals. The D2F2/PRL-3 tumor challenge in the preventive and therapeutic protein vaccination was performed as described above.
ELISA assay for detecting PRL-3 antibody
The purified PRL-3 protein (1 mg ml À 1 sodium carbonate, pH 9.5) was coated on 96-well plates with 50 ml per well and incubated overnight at 4 1C. The indirect ELISA assay was described previously to detect the antibody. 52 The titer of anti-PRL-3 antibody in experimental mouse sera was determined by serial dilution.
Cytokines assays
After the mice were killed, spleens were aseptically removed and the spleen cells were suspended in RPMI 1640 with 10% fetal bovine serum at a density of 5 Â 10 6 per ml and cultured in flat-bottomed 24-well plates. Splenocytes were cultured in triplicate (1 ml per well), and stimulated with or without indicated adjuvant-PRL-3 fusion proteins (10 mg ml À 1 ) plus phytohemagglutinin (10 mg ml À 1 ) for 48 h at 37 1C and 5% CO 2 . Supernatants of splenocytes cultures were collected and assayed for T-helper type 1 and T-helper type 2 cytokines using SearchLight Anti-Mouse Cytokine Arrays (catalog no. 84649) with Aushon SearchLight Multiplex Immunoassay by Lightarray Biotech (Shanghai, China). Alternatively, total RNA from splenocytes isolated using TRIZOL reagent (Invitrogen) were subjected to qRT-PCR for IFN-g and IL-4 assay. The primers used were as follows: IFN-g (forward: 
